The immense amount of electronic health data (pharmacy and administrative claims, electronic health records, and clinical registries) that is being generated every day in the care of patients has the potential to be leveraged for improving clinical decisions at the point of care, uncovering or validating drug efficacy and drug safety. The potential use of big data for improving safe and effective use of medications is especially important in children because of their low drug exposure relative to adults. Electronic health data is collected primarily for clinical or billing purposes and not for research purposes. The major steps involved in data acquisition, extraction, aggregation, analysis, modeling, and interpretation are discussed. It is important to understand the limitation of big data and utilize appropriate study design and statistical methods. Possible applications are presented along with specific examples of how big data has been used in drug research to find that blip on the radar screen that may give an efficacy or safety signal that can lead to further investigation.
1
Wikipedia defines big data as a data set so large and complex that standard data processing applications are inadequate for analysis. 2 We see the effect of big data analytics in our everyday lives, especially through ecommerce, whether shopping online at Amazon, watching movies on Netflix, or communicating with any number of social media platforms. Because of our interaction with these technologies, we are sent e-mails or have advertisements on web pages we are browsing suggesting other products based on our purchases, online searches for products, and our viewing or rating of movies. 3 Big data is described by the characteristics of volume, velocity, and variety. Big data is usually in the range of 1 petabyte (10 15 ) or more in size. Electronic health care data volume reached 150 exabytes (10 18 ) in 2011 and with the velocity in growth is expected to soon exceed 10 [21] [22] [23] [24] gigabytes, although much of this data is unstructured in doctor notes, or stored in patient monitoring and wearable devices. 4, 5 Improvements in the collection, integration, and availability of a large variety of electronic health data (pharmacy and administrative claims, electronic health records [EHRs] , and clinical registries) have provided opportunities for research. The amount of data that is being generated every day in the care of patients has the potential to be leveraged for improving clinical decisions at the point of care, uncovering or validating drug efficacy and drug safety surveillance. 6 Understanding the type and quality of data available is essential to using electronic health data for clinical discovery.
Within health care we are approaching near universal adoption of EHRs at some level among hospitals and physician clinics. 7 EHRs are generating massive volumes of data through the provision of patient care that includes structured data (laboratory values, demographic parameters, dispensed medications, diagnostic data) and unstructured data (physician progress notes, discharge summaries). 6 The data are longitudinal, containing diverse patient populations with repeated observations. Individual data sets can be S87 quite large (ie, digitalized magnetic resonance images or gene microarray data). EHRs provide opportunities for generating sets of medication-treated cases and controls for comparative effectiveness research. This potential is especially important in children because of the limited amount of published data available on the safe and effective use of medications. Except for a few diseases (ie, asthma, attention deficit disorder, autism, obesity, and acute infection) essentially all other pediatric illnesses are rare diseases, which limits the number of pediatric patients available to participate in clinical trials. 8, 9 The use of EHR data to generate evidence for the potential benefits of medication therapy is appealing. Because drug exposure is low in children, electronic health data aggregated from multiple sources give investigators access to larger numbers of patients to answer questions about improving safe and effective use of medications in children. 7 This review will summarize the major steps involved in the analysis of big data, including the limitations of big data and the possible applications, and will end with specific examples of how big data has been used in drug research to find that blip on the radar screen that may give an efficacy or safety signal that can lead to further investigation.
Major Steps in the Analysis of Big Data
A recent white paper from Agrawal 10 describes the steps involved in the analysis of big data that include data acquisition, extraction/cleaning, integration/aggregation, analysis/modeling, and interpretation.
There are a multitude of open-access and private health care data resources that can be acquired for studying drug therapy and adverse drug events. Examples of databases (Table 1 ) available for clinical research in children include institutional EHR data (hospitals and clinics), aggregated EHR data (ie, Cerner Health Facts R ), and administrative claims data (ie, Market Scan R , QuintilesIMS TM ). There are also pediatric-specific databases such as the Pediatric Health Information System R (PHIS, Children's Hospital Association), 11 Kids' Inpatient Database (KID) that is part of the Healthcare Cost and Utilization Project (HCUP, AHRQ) 12 and Pediatric Research in Office Settings (PROS, AAP). 13 There are specific population databases such as neonatal databases (Vermont Oxford Network databases, Kaiser Permanente Neonatal data set), critically ill children databases, 14 disease-specific registries (ie, Cystic Fibrosis Foundation Registry, Children's Oncology Group Registry, Pediatric Heart Failure Registry), and pediatric learning health systems (Pedsnet, ImproveCareNow, and Comparative Effectiveness Research Through Collaborative Electronic Reporting). 13, 15 Extracting the data of interest correctly and completely remains a challenge. Depending on the questions asked of the data, much of the information collected is of no interest to the investigator and can be filtered, but it is important not to discard useful information in the process since many different parts of the data could potentially be useful for many different types of projects. An important step in the process of data extraction is patient selection. There rarely exists a single data item that will identify all patients that satisfy diagnosis criteria. 16 Usually, algorithms for selecting relevant patient records must be developed. The eMERGE network is one example of a collaborative group that has developed a large number of algorithms to capture relevant data collected during routine clinical care. 17, 18 These algorithms can be constructed using patientderived information such as the International Classification of Diseases (ICD 9/10) codes, procedure codes (Current Procedural Terminology), laboratory values, drug therapy, and physician notes. Natural language process tools allow the exploration of textual data and can give structure to unstructured raw data. 19 For example, text mining techniques can extract structured data such as the drug name, dosage, and frequency from physician progress notes. Subsequent cleaning and validating of data is essential. Validation can be through internal processes or external by corroboration with other studies or data from different sources.
Big data must be aggregated, often from many different data sources that require a complex data process application for the appropriate integration of the data for analysis. Aggregation can also include a process of reducing the number of variables; for example, for drug therapy, using therapeutic classes in place of individual active ingredients can significantly reduce the number of variables in an analysis model.
Limitations in Big Data Analysis
While observational data are less costly and potentially useful when randomized controlled trials are not feasible or ethical, studies using big data must be approached with caution. Researchers need to understand the limitations and utilize appropriate study design and statistical methods. 20 It is important to understand that EHR data are collected primarily for clinical or billing purposes and not for research purposes. 21 Therefore, diagnostic and therapeutic procedures were conducted only when deemed medically necessary as opposed to specified intervals in randomized controlled trials (RCTs). 22 Medical record data are not always capable of supporting extraction, aggregation, or identification of patient groups. Accuracy and completeness of data are important factors that impact the inferences that can be made from any analysis. 23 Errors in omission 
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and commission occur in these data arising from data entry, transfer, and extraction. These databases do not capture patient mobility in and out or across multiple systems, changes in providers and insurance, nor do they capture individuals experiencing barriers to care such as the uninsured and rare users of health care. Only about 40% of patients are currently captured in EHRs, and medical care may account for only 10% of the variance in health outcomes. The Institute of Medicine has called for the capture of social, environmental, and behavioral factors because it may account for about half the variance in outcome, but these data are rarely captured in EHRs. 24 Also, event-driven health care visits bias toward the overestimation of illness and disability.
Misclassification bias remains a problem due to reliance on diagnosis codes and other patient descriptor criteria to ascertain cases. Specifically, for most health care data derived from EHRs or claims data, there frequently is an absence of diagnoses or indication for medication treatment. Although assumptions may be made when attributing prescribed medication to a condition, use outside the presumed indication cannot be ruled out (ie, metformin for type 2 diabetes vs "off-label" for weight loss). EHR data can be very heterogeneous, especially when aggregating data from multiple institutions. There can be inconsistent use of medical terminology (ie, hypertension, elevated blood pressure, high blood pressure; or kidney disease, kidney failure, renal failure, acute renal failure, acute kidney injury, acute kidney disease, acute kidney disorder) or misspelling such as ileum versus ilium. 25 Data quality is always challenging where missing data is common and not the exception. Structured data can be associated with significant measurement error or imprecision (ie, serial height measurements recorded in the EHR where the patient apparently grows and shrinks over time). Multiple sources of data without clear indication of which is the definitive source is a challenge; that is, drug administration, drug order prescribing, pharmacy dispensing, medication administration, and medication reconciliation records are each surrogates of the truth as to whether the patient received the drug. A major difference between relatively small research protocol data and clinical care data used in big-data analyses, is that research protocols are highly structured and there is conformity among investigators, whereas clinical care can be very divergent among health care institutions and even among health care providers within institutions.
Big data analytics require new statistical approaches. Standard statistical methods assume that the data sample is small relative to the population it represents and make inferences from the data sample to formulate conclusions that can be generalized to the entire population. [26] [27] [28] In contrast, big data represents a substantial percentage or possibly the entire population, and statistical analysis morphs into the analytical aims of prediction and inferences based on modeling of all elements of big data using exploratory, classification, and pattern-tracking methods. 27 The findings from the analysis of big data is highly dimensional and can result in statistically significant but unimportant (trivial) differences in clinical outcome because the effect size (magnitude of treatment effect) declines as a function of sample size. 25, 29 Further, spurious correlations of uncorrelated independent random variables can increase with the size of the data set. 26, 27 Data analysis is also complicated by the heterogeneity of the data that are often derived from multiple sources.
Application of Big Data Analysis to Drug Efficacy and Drug Safety
Understanding the clinical effectiveness and safety of a therapeutic intervention is the most important factor for clinicians. They are faced with making therapeutic decisions based on the limited efficacy information that is available because the strict conditions utilized in RCTs may be attenuated or completely lost when applied to real-world care. 30 However, most patients treated clinically are not reflected in the highly selected participants in RCTs. These patients are far more complicated, with multiple comorbidities and concurrent therapy that are severely restricted in RCTs. RCTs often produce conflicting results that are reflective of the differences in study design that result in distinct groups of patients and study procedures, necessitating the need for multiple RCTs to establish a "gold standard." Welldesigned observational studies may be less prone to these varied results due to a broader representation of the population at risk. 31 Big data's large sample size allows a better understanding of the heterogeneity in the patient population and allows the exploration of the association of certain covariates, such as why certain subpopulations of children respond to certain drug therapy and why other children experience harm. 13 It may be possible to evaluate the effect of polypharmacy on response to therapy that is not possible under the highly restrictive RCT. Electronic health care data have been leveraged to support large-scale pharmacoepidemiologic research to study medication use, efficacy, and safety. 13 EHRs are useful for evaluating health care resource use, adoption of new therapies, and the effect of policy and guidelines on medication use. 9 Big data analytics will also play a major role in medical decision making and implementation of precision medicine through the integration of the genomic, transciptomic, and proteomic character of the host and/or the disease with the
S90
The Journal of Clinical Pharmacology / Vol 58 No S10 2018 enormous amount of published literature to determine the optimal treatment for a specific patient. 32 Postmarketing observational studies are heavily relied upon in children for safety evaluation. [33] [34] [35] EHRs and claims databases offer a rich source of data to perform safety studies. Osokogu et al. 36 reported their systematic review of pharmacoepidemiologic safety studies in children. They found the number of pharmacoepidemiologic safety studies to be low, with most being done in developed countries. With the passage of pediatric legislation in the United States and other countries, they have observed an increase in pediatric safety studies since 2002. de Bie et al. 7 used data from 7 EHR databases in 3 European countries during a 15 year period to estimate the number of drugs and drug classes for which there was sufficient drug exposure to estimate specific adverse events as a function of drug use. They found that half of the total drug exposure was seen with only 18 drugs, only 0.8% of the total number of drugs children were exposed to during the study period. Although children made up 20% of the population in the drug safety database, they contributed only 3% of the total drug exposure.
Examples of Observational Studies Evaluating Drug Efficacy and Drug Safety
Eight studies were identified as examples of medication outcome studies in children using big data ( Table 2) . Three of the studies evaluated the comparative effectiveness of asthma therapies in children 4 to 17 years of age. The first study used both health plans and Medicaid data to identify more than 26,000 children and determined that there was no association of asthma exacerbation risk among the controller medications (montelukast, inhaled corticosteroid, or long-acting beta-agonists), but the overall use of these medications was low in this population. 37 In the second comparative effectiveness study, an integrated-outcome database was used to identify nearly 5000 children who received either inhaled fluticasone or montelukast to compare treatment failure, hospitalization, and total cost of care. 38 The study found that children treated with montelukast were more than 2 times as likely to experience treatment failure and be admitted to the hospital, and incurred greater asthma-treatment related costs. The third study compared the effectiveness of prednisone versus dexamethasone in more than 40,000 children hospitalized with asthma exacerbation not requiring intensive care. 39 Dexamethasone treatment was associated with a shorter length of stay and a lower cost index; however, there was no difference in intensive care unit transfer or readmission.
Two infectious disease-related studies were identified. The first studied a total of 152 children with recurrent urinary tract infections who either received antibiotic prophylaxis or endoscopic injection with dextranomer/hyaluronic acid copolymer as a curative option. 40 The injection therapy resulted in significantly fewer urinary tract infections. In the second study, medical and pharmacy records from 2 health maintenance organizations were used to examine incidence and characteristics contributing to varicella breakthrough in the period following vaccination. 41 No significant associations were found between proposed risk factors (asthma, steroid use) and varicella breakthrough.
Three studies evaluating drug safety in children were identified. Medicaid medical and pharmacy claims data were used to demonstrate the increased incidence of type 2 diabetes associated with the initiation of second-generation antipsychotics and concomitant therapy with antidepressants and certain newer antipsychotics. 42 Electronic patient records from the Pedianet network was used to evaluate mucocutaneous reactions arising from the use of niflumic acid, nonopioid analgesics, and other nonsteroidal antiinflammatory drugs in children. 43 The authors concluded that the use of niflumic acid did not increase the risk of mild or severe mucocutaneous reactions. A study using the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance and national retail pharmacy prescription data from IMSHealth TM evaluated emergency hospitalizations for unsupervised prescription medication ingestions in young children (<6 years). 44 Three-quarters of hospitalizations for unsupervised prescription medication ingestions involved 1 and 2 year-old children; 1 in 5 hospitalizations involved ingestion of 2 medications; and opioids and benzodiazepines were the most commonly implicated medication classes.
Examples of Observational Studies Compared With RCTs
The use of EHRs to replicate the results of randomized controlled trials has seen mixed results (Table 3) . 45 There are more examples of these types of studies in adults. An adult study using the United Kingdom General Practice Research database replicated the results of 2 RCTs of angiotensin-converting enzyme inhibitors. 45, 46 The initial analysis of the database suggested a poorer cardiovascular outcome. It was only after adjustment of prior events in the cohorts prior to the start of the study to adjust the hazard ratio that the authors were able to replicate the RCTs. Similar challenges were found with studies into the impact of hormone replacement therapy upon cardiovascular health. 47, 48 The Nurse Health Observational study in the 1990s found an overall cardiovascular benefit to women with hormone replacement therapy. 48, 49 The subsequent randomized study found increased cardiovascular risk for hormone replacement therapy. 50 A perspective on these and other hormone replacement studies points out the difference in the study populations, the importance of age, and the time from menopause. The younger age of women in the early stage of menopause hormone replacement therapy neither protects nor increases the risk of cardiovascular disease; however, women over 70 years of age or more than 20 years after the onset of menopause have an increased cardiovascular risk. 51 There are very few published reports in children that have attempted to replicate RCTs with observational data. In one comparative effectiveness study, the efficacy of anti-tumor necrosis factor-α agents in the management of moderate to severe Crohn disease was evaluated using the ImproveCareNow database. 52 ImproveCareNow is a collaborative network of over 100 pediatric gastroenterology centers that, together with researchers, patients, and parents, seeks to improve inflammatory bowels disease care. Participating centers collect standardized data during all clinic visits. In routine pediatric gastroenterology practices, anti-tumor necrosis factor-α therapy resulted in corticosteroidfree remission in patients with Crohn disease. These observational study results were compared against 2 prospective controlled trials, the REACH (Rehabilitation Early for Congenital Hemiplegia) study (pediatric trial) and SONIC (Study of Biologic and Immunomodulator Naïve Patients in Crohn's Disease) study (adult trial). The results were consistent with those seen with the use of anti-tumor necrosis factor-α for induction and maintenance therapy in children and the controlled trial in adults. 53, 54 A comparative effectiveness study of diabetes drugs showed agreement between observational studies and published clinical trials. 55 Randomized trials of second-line diabetes oral therapy (thiazolidinedione, sulfonylurea, or DDP-4 inhibitor) in addition to metformin monotherapy were identified. The United Kingdom Health Information Network database was used to estimate the effect of the second-line drug therapy on the change in HbA 1c prior to extracting the findings of the randomized controlled trials. 56 No difference was found between the meta-analyzed randomized trials and the simulated observation results on changes in HbA 1c .
Conclusions
This review summarizes the potential for leveraging big data to support evidence based on medication use that can define drug safety and risk as well as provide evidence of drug efficacy in routine pediatric practice. There remains considerable controversy over whether observational studies can provide reliable information on the safety and effectiveness of drug therapy. It is unlikely that observational studies will replace RCTs, but they can supplement their findings. Observational studies may help in expanding the generalization of the findings of RCTs to a broader, more heterogeneous patient population.
